002821 凯莱英
已收盘 05-07 15:00:00
资讯
新帖
简况
凯莱英（002821）披露H股证券变动月报表，5月6日股价下跌0.7%
证券之星 · 05-06 22:14
凯莱英（002821）披露H股证券变动月报表，5月6日股价下跌0.7%
凯莱英：公司持续提升连续性反应以及各项新技术的应用率
证券之星 · 05-06 16:45
凯莱英：公司持续提升连续性反应以及各项新技术的应用率
花旗集团在凯莱英H股长仓比重降至7.11% 较4月28日9.86%显著收缩
美股速递 · 05-05 17:32
花旗集团在凯莱英H股长仓比重降至7.11% 较4月28日9.86%显著收缩
摩根大通持仓凯莱英H股比例降至7.64% 较上月减持0.54个百分点
美股速递 · 05-04
摩根大通持仓凯莱英H股比例降至7.64% 较上月减持0.54个百分点
每周股票复盘：凯莱英（002821）Q1营收增16.91%至18.02亿元
证券之星 · 05-03
每周股票复盘：凯莱英（002821）Q1营收增16.91%至18.02亿元
凯莱英遭Schroders PLC减持25.89万股 每股作价约113.53港元
新浪港股 · 04-30
凯莱英遭Schroders PLC减持25.89万股 每股作价约113.53港元
Norges Bank减持凯莱英(06821)18.49万股 每股作价约102.86港元
智通财经 · 04-29
Norges Bank减持凯莱英(06821)18.49万股 每股作价约102.86港元
交银国际：上调凯莱英(06821)目标价至136.6港元 维持“买入”评级
智通财经 · 04-29
交银国际：上调凯莱英(06821)目标价至136.6港元 维持“买入”评级
凯莱英(06821)股东将股票由花旗银行转入摩根士丹利香港证券 转仓市值1.77亿港元
智通财经 · 04-29
凯莱英(06821)股东将股票由花旗银行转入摩根士丹利香港证券 转仓市值1.77亿港元
和讯信息张汇：创业板4连阴！科技股要分化？
和讯网 · 04-28
和讯信息张汇：创业板4连阴！科技股要分化？
凯莱英涨10.00%，开源证券三周前给出“买入”评级
证券之星 · 04-28
凯莱英涨10.00%，开源证券三周前给出“买入”评级
别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？
格隆汇 · 04-28
别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？
港股异动 | 凯莱英(06821)涨超10% 一季度经调整归母净利增近28% 新兴业务收入同比大增七成
智通财经 · 04-28
港股异动 | 凯莱英(06821)涨超10% 一季度经调整归母净利增近28% 新兴业务收入同比大增七成
异动快报：凯莱英（002821）4月28日9点39分触及涨停板
证券之星 · 04-28
异动快报：凯莱英（002821）4月28日9点39分触及涨停板
凯莱英：一季度净利润3.04亿元 同比减少6.82%
南方财经网 · 04-27
凯莱英：一季度净利润3.04亿元 同比减少6.82%
高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等
智通财经 · 04-27
高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等
凯莱英尾盘涨超5%
每日经济新闻 · 04-27
凯莱英尾盘涨超5%
港股异动 | 凯莱英(06821)尾盘涨超5% 20亿元化学大分子CDMO项目落地天津 TIDES持续扩能扩产
智通财经 · 04-27
港股异动 | 凯莱英(06821)尾盘涨超5% 20亿元化学大分子CDMO项目落地天津 TIDES持续扩能扩产
凯莱英午后涨近6%
每日经济新闻 · 04-24
凯莱英午后涨近6%
港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区
智通财经 · 04-24
港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区
加载更多
公司概况
公司名称：
凯莱英医药集团(天津)股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-18
主营业务：
凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。
发行价格：
30.53
{"stockData":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":128.08,"timestamp":1778137386000,"preClose":124.68,"halted":0,"volume":7829843,"delay":0,"changeRate":0.0273,"floatShares":317000000,"shares":361000000,"eps":3.0767,"marketStatus":"已收盘","change":3.4,"latestTime":"05-07 15:00:00","open":124.98,"high":131.29,"low":124.98,"amount":1007000000,"amplitude":0.0506,"askPrice":128.09,"askSize":3,"bidPrice":128.08,"bidSize":20,"shortable":0,"etf":0,"ttmEps":3.0767,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":5,"adr":0,"adjPreClose":124.68,"symbolType":"stock","openAndCloseTimeList":[[1778117400000,1778124600000],[1778130000000,1778137200000]],"highLimit":137.15,"lowLimit":112.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":360874970,"isCdr":false,"pbRate":2.51,"roa":"--","peRate":41.629018,"roe":"1.71%","epsLYR":3.16,"committee":0.611374,"marketValue":46221000000,"turnoverRate":0.0247,"status":0,"hkstockBrief":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":105.6,"timestamp":1778141291007,"preClose":98.85,"halted":0,"volume":690140,"delay":0,"premium":"-28.43"},"floatMarketCap":40607000000},"requestUrl":"/m/hq/s/002821/","defaultTab":"news","newsList":[{"id":"2633131181","title":"凯莱英（002821）披露H股证券变动月报表，5月6日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131181","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131181?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:14","pubTimestamp":1778076864,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，凯莱英报收于124.68元，较前一交易日下跌0.7%，最新总市值为449.94亿元。该股当日开盘123.2元，最高125.48元，最低120.8元，成交额达10.32亿元，换手率为2.63%。近日，凯莱英医药集团（天津）股份有限公司披露《证券变动月报表》。公告显示，截至2026年4月30日，公司H股总数为27,834,510股，全部已发行并上市；A股总数为333,040,460股，其中已发行331,889,160股，库存股1,151,300股。公司确认H股类别已满足联交所规定的公众持股量要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK1191","06821","002821","LU1328615791.USD","161027","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633900974","title":"凯莱英：公司持续提升连续性反应以及各项新技术的应用率","url":"https://stock-news.laohu8.com/highlight/detail?id=2633900974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633900974?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:45","pubTimestamp":1778057123,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英05月06日在投资者关系平台上答复投资者关心的问题。基于公平公正的信息披露原则和CDMO行业准则以及商业秘密保护的义务，公司不便回复未曾披露的订单对应主要成分\\主要结构等详细信息。公司持续提升连续性反应以及各项新技术的应用率，在研发投入也保持行业领先。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600025210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0132","06821","002821","LU1328615791.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160542788","title":"花旗集团在凯莱英H股长仓比重降至7.11% 较4月28日9.86%显著收缩","url":"https://stock-news.laohu8.com/highlight/detail?id=1160542788","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160542788?lang=zh_cn&edition=full","pubTime":"2026-05-05 17:32","pubTimestamp":1777973540,"startTime":"0","endTime":"0","summary":"香港交易所最新披露数据显示，花旗集团对凯莱英（Asymchem Laboratories）H股的持股权比例出现明显调整。截至4月28日，其长仓持仓比例从先前公布的9.86%下降至7.11%，减持幅度达2.75个百分点。\n此次持股变动引发市场关注，机构投资者对医药外包服务板块的配置策略可能正在发生微妙变化。作为全球领先的医药研发生产服务商，凯莱英的H股流动性向来备受国际资本青睐。花旗集团此次仓位调整是否预示其对CXO行业前景的重新评估，值得进一步观察。\n二级市场数据显示，近期生物医药板块整体面临估值回调压力，机构持仓结构的变化往往成为行业风向标。投资者需密切关注后续可能出现的连锁反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","BK0132","BK0239","06821","BK1191","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157054122","title":"摩根大通持仓凯莱英H股比例降至7.64% 较上月减持0.54个百分点","url":"https://stock-news.laohu8.com/highlight/detail?id=1157054122","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157054122?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:27","pubTimestamp":1777886836,"startTime":"0","endTime":"0","summary":"根据香港交易所最新披露文件显示，国际投行摩根大通对凯莱英医药集团H股的持股比例出现调整。截至4月28日，其长期持仓比例已从先前公布的8.18%降至7.64%，减持幅度达0.54个百分点。\n此次持股变动引发市场对机构投资者策略的关注。作为全球领先的医药研发生产服务商，凯莱英近年来持续获得资本市场的青睐。摩根大通此次持仓调整或反映其对该股估值水平的重新评估，亦可能基于投资组合再平衡的常规操作。\n值得关注的是，此次披露的持股比例变化仅涉及H股部分。根据公开信息，凯莱英同时在内地A股市场上市，两地股价走势及机构持仓策略往往存在联动效应。投资者需综合考量企业基本面、行业政策环境及市场流动性等多重因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002821","LU1328615791.USD","BK1191","06821","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632267153","title":"每周股票复盘：凯莱英（002821）Q1营收增16.91%至18.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632267153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632267153?lang=zh_cn&edition=full","pubTime":"2026-05-03 01:37","pubTimestamp":1777743429,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，凯莱英报收于125.56元，较上周的117.08元上涨7.24%。本周，凯莱英4月28日盘中最高价报129.49元。本周关注点业绩披露要点：凯莱英2026年一季度主营收入18.02亿元，同比上升16.91%。业绩披露要点凯莱英2026年一季报显示，一季度公司主营收入18.02亿元，同比上升16.91%；归母净利润3.04亿元，同比下降6.82%；扣非净利润2.72亿元，同比下降10.88%；负债率13.25%，投资收益2477.27万元，财务费用7814.91万元，毛利率43.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631469575","title":"凯莱英遭Schroders PLC减持25.89万股 每股作价约113.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631469575","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631469575?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:01","pubTimestamp":1777507260,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，4月28日，Schroders PLC减持凯莱英（06821）25.89万股，每股作价113.5268港元，总金额约为2939.21万港元。减持后最新持股数目为538.03万股，最新持股比例为19.33%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-30/doc-inhwfpqn7266535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","002821","BK0132","EWH","BK0239","LU1328615791.USD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631512887","title":"Norges Bank减持凯莱英(06821)18.49万股 每股作价约102.86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631512887","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631512887?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:55","pubTimestamp":1777467357,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月27日，Norges Bank减持凯莱英(06821)18.49万股，每股作价102.8593港元，总金额约为1901.87万港元。减持后最新持股数目为405.66万股，最新持股比例为14.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","002821","BK0132","EWH","BK0239","LU1328615791.USD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551724","title":"交银国际：上调凯莱英(06821)目标价至136.6港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631551724?lang=zh_cn&edition=full","pubTime":"2026-04-29 10:31","pubTimestamp":1777429898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将凯莱英(06821,002821.SZ)H股目标价调高至136.6港元，A 股为159.2元人民币，维持“买入”的投资评级。基于首财季的超预期业绩表现，交银国际上调凯莱英2026-28年经调整净利润预测2-14%。该行指，尽管面临汇率波动和小份子业务高基数的影响，该公司在2026年首财季录得强劲且超预期的利润增长，反映出新兴业务订单需求的持续高涨和经营效率的提升。公司在高景气度赛道的后期订单规模扩大和前瞻性投入，可望带来较强的长期高增长确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","EWH","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553574","title":"凯莱英(06821)股东将股票由花旗银行转入摩根士丹利香港证券 转仓市值1.77亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553574","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631553574?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:17","pubTimestamp":1777421853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月28日，凯莱英(06821)股东将股票由花旗银行转入摩根士丹利香港证券，转仓市值1.77亿港元，占比6.06%。凯莱英发布2026年第一季度业绩，营业收入约18.02亿元，同比增长16.91%；归属于上市公司股东的净利润约3.04亿元，同比减少6.82%；扣非净利约2.72亿元，同比减少10.88%；基本每股收益0.84元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4534","LU0225283273.USD","161027","LU0158827781.USD","BK4581","LU0162691827.USD","LU0106831901.USD","LU1366192091.USD","LU0314106906.USD","LU2023251221.USD","LU2271345857.HKD","LU0006306889.USD","LU1074936037.SGD","LU0477156953.USD","LU0795875169.SGD","LU0072461881.USD","LU1732799900.SGD","LU0528227936.USD","BK4559","BK4588","BK4127","LU0106261372.USD","BK4516","LU1244550494.USD","BK4504","LU1791710400.SGD","LU0158827948.USD","LU2133065610.SGD","LU0130102774.USD","LU2028103732.USD","LU0052756011.USD","LU1668664300.SGD","LU1201861249.SGD","LU0320765646.SGD","LU1162221912.USD","LU1244550577.SGD","LU1328615791.USD","06821","LU2125154778.USD","LU0795875086.SGD","BK4566","LU1244550221.USD","002821","LU1791710582.SGD","LU0130517989.USD","LU0170899867.USD","LU2089284900.SGD","LU1791807156.HKD","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630302781","title":"和讯信息张汇：创业板4连阴！科技股要分化？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630302781","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630302781?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:48","pubTimestamp":1777380532,"startTime":"0","endTime":"0","summary":"4月28日，和讯信息张汇分析称今天三大指数继续调整，但分化也是很明显，这两天主板没怎么跌，整体震荡，但创业板已经连调四天，今天已经跌破了10日线，万物皆轮动，月初怎么涨的，月末就怎么调，还好，这月整体涨幅还是可以的。整体而言，随着节前效应逐步显现，目前市场还是以震荡轮动为主，把握个股节奏是关键。药名昨晚一季报，营业收入、归母净利润均创下历史同期新高，超出预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.hexun.com/2026-04-28/224076840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","000905.SH","002821","159915","512510","399001","510880","159967","603259","06821","BK4585","000300.SH","515890","000688.SH","02359","510300","BK4588","512880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630376304","title":"凯莱英涨10.00%，开源证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630376304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630376304?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:31","pubTimestamp":1777365114,"startTime":"0","endTime":"0","summary":"今日凯莱英涨10.00%，收盘报129.49元。2026年4月1日，开源证券研究员余汝意发布了对凯莱英的研报《公司信息更新报告：收入利润高质增长，多赛道景气共振下迈向加速周期》，该研报对凯莱英给出“买入”评级。研报中预计2026-2028年公司归母净利润为15.07/18.59/23.12亿元，EPS为4.18/5.15/6.41元，当前股价对应PE为24.1/19.5/15.7倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中国银河的宋丽莹、程培。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","06821","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630132145","title":"别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630132145","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630132145?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:12","pubTimestamp":1777349565,"startTime":"0","endTime":"0","summary":"新一轮行情蓄势待发？","market":"us","thumbnail":"https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4574522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU2045819591.USD","002821","LU2242644610.SGD","LU1046422090.SGD","CHAT","603127","LU1328615791.USD","BK1515","ARTY","BK1574","BK0132","CXO","06821","BK1141","LU2125910500.SGD","LU0348766576.USD","BK0216","BK1161","AIPO","LU0320764599.SGD","AGIX","159938","BK0239","BK1576","02359","BK1191","LU0052750758.USD","LU0708995583.HKD","09939","BK1583","LU0348767384.USD","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630323318","title":"港股异动 | 凯莱英(06821)涨超10% 一季度经调整归母净利增近28% 新兴业务收入同比大增七成","url":"https://stock-news.laohu8.com/highlight/detail?id=2630323318","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630323318?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:22","pubTimestamp":1777346548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英涨超10%，截至发稿，涨10%，报115.5港元，成交额1.72亿港元。消息面上，4月27日晚，凯莱英发布2026年第一季度业绩，营业收入约18.02亿元，同比增长16.91%；归属于上市公司股东的净利润约3.04亿元，同比减少6.82%。分业务来看，一季度小分子CDMO 业务收入12亿元，同比增长 0.43%，恒定汇率下增长 3.26%；新兴业务收入5.98亿元，同比增长74.07%，主要是化学大分子和生物大分子业务板块增长强劲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","LU1328615791.USD","BK1191","BK4588","BK0132","VXUS","BK0239","002821","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630475973","title":"异动快报：凯莱英（002821）4月28日9点39分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2630475973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630475973?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:40","pubTimestamp":1777340457,"startTime":"0","endTime":"0","summary":"证券之星4月28日盘中消息，9点39分凯莱英触及涨停板。其所属行业医疗服务目前上涨。领涨股为普瑞眼科。该股为减肥药，健康中国，合成生物概念热股，当日减肥药概念上涨1.37%，健康中国概念上涨1.22%，合成生物概念上涨0.77%。4月27日的资金流向数据方面，主力资金净流入8185.01万元，占总成交额7.84%，游资资金净流入2559.26万元，占总成交额2.45%，散户资金净流出1.07亿元，占总成交额10.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800029854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0132","BK0239","06821","BK1191","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630367452","title":"凯莱英：一季度净利润3.04亿元 同比减少6.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630367452","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630367452?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:20","pubTimestamp":1777285200,"startTime":"0","endTime":"0","summary":"【凯莱英：一季度净利润3.04亿元 同比减少6.82%】凯莱英公告，2026年第一季度实现营业收入18.02亿元，同比增长16.91%；归属于上市公司股东的净利润3.04亿元，同比减少6.82%；经营活动产生的现金流量净额5.27亿元，同比增长17.21%。净利润同比下降主要系本期人民币升值导致汇兑损失增加，而上年同期为汇兑收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720337241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06821","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364329","title":"高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364329?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:25","pubTimestamp":1777281907,"startTime":"0","endTime":"0","summary":"股份方面，该行对评级为“买入”的股份持更正面态度，包括药明康德 、凯莱英 、微创机器人 及精锋医疗 。另外，该行将爱康医疗 评级升至“买入”，反映其执行力重启、利润率改善及中期能见度更清晰，并将微泰医疗 升级至“中性”，因国内竞争影响优于预期，且有序达成2026年指引。前者受累于持续的VBP相关利润压力及短期增长乏力，后者收入加速回升但仍不明朗，上行空间有限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK0132","LU1808992512.USD","LU2242644610.SGD","LU0456842615.SGD","LU0348766576.USD","BK1222","LU0287142896.SGD","LU2125910500.SGD","06821","02252","LU0708995583.HKD","LU1934453819.USD","BK1100","01066","BK1141","BK1576","LU1328615791.USD","LU2488822045.USD","LU0173614495.USD","LU2045819591.USD","LU1997244956.HKD","LU1969619763.USD","CDMO","BK0216","LU1997245177.USD","02675","LU0320764599.SGD","BK1585","LU1979443071.USD","BK1191","LU2328871848.SGD","002821","BK1583","LU0348767384.USD","BK0239","603259","LU0052750758.USD","BK1617","02359","LU2495084118.USD","LU1997245094.SGD","01789","BK1589","LU1046422090.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630736342","title":"凯莱英尾盘涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630736342","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630736342?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:47","pubTimestamp":1777276022,"startTime":"0","endTime":"0","summary":"4月27日，凯莱英(06821.HK)尾盘涨超5%，截至发稿涨5.13%，报104.5港元，成交额1.18亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720073386.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720073386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","BK0239","06821","LU1328615791.USD","002821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630635623","title":"港股异动 | 凯莱英(06821)尾盘涨超5% 20亿元化学大分子CDMO项目落地天津 TIDES持续扩能扩产","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635623","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630635623?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:41","pubTimestamp":1777275714,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英(06821)尾盘涨超5%，截至发稿，涨5.13%，报104.5港元，成交额1.18亿港元。消息面上，凯莱英化学大分子CDMO项目落地天津经开区。该项目将进一步提升公司在多肽、寡核苷酸（TIDES）等新分子类型的CDMO一站式服务能力，更好满足全球合作伙伴的多元需求。浙商证券此前指出，考虑到凯莱英小分子CDMO不错的在手PPQ项目，我们认为小分子CDMO业务仍具有较强的成长性。新兴业务板块多肽、寡核苷酸、ADC相关CDMO、制剂CDMO等仍有较大的成长空间和业绩弹性，","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002821","LU1328615791.USD","BK4139","BK4585","CDMO","BK0239","VXUS","BK4588","06821","BK0132","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629890926","title":"凯莱英午后涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629890926","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629890926?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:29","pubTimestamp":1777012197,"startTime":"0","endTime":"0","summary":"4月24日，凯莱英(06821.HK)午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243717891296.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243717891296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","LU1328615791.USD","002821","06821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629974938","title":"港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629974938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629974938?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:26","pubTimestamp":1777011981,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。公开数据显示，2025年凯莱英化学大分子CDMO板块实现营业收入10.28亿元，同比增长123.72%，成为公司增长最为迅速的业务单元。公司预计26年多肽PPQ项目将达4个且多肽固相合成产能将从25年底的4.5万升增至26年底的6.9万升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","BK0132","BK4588","BK4139","CDMO","BK1191","159992","002821","BK4585","BK0239","BK1161","VXUS","BK1574","06978","06821"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778163374699,"stockEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.2164},{"period":"6month","weight":0.3098},{"period":"1year","weight":0.5213},{"period":"ytd","weight":0.3417}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0722},{"period":"3month","weight":0.0207},{"period":"6month","weight":0.0407},{"period":"1year","weight":0.2545},{"period":"ytd","weight":0.0482}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"凯莱英医药集团(天津)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2016-11-18","address":"天津市滨海新区经济技术开发区洞庭三街6号","registeredCapital":"36087万元","survey":" 凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。","listedPrice":30.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,002821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}